Uroplasty Inc

Uroplasty — Merger or Acquisition (December 2014)

22 slides from Uroplasty's merger presentation, Dec 22, 2014

  1. Slide 1: Creating a Medical Device Company Positioned for Growth

    December 2014 Creating a Medical Device Company Positioned for Growth Filed by Uroplasty, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Uroplasty, Inc. Commission File No. 001-32632

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of

  3. Slide 3: Important Additional Information About This Transaction and Where to Find It

    Important Additional Information About This Transaction and Where to Find ItIn connection with the proposed merger, Vision-Sciences plans to file with the SEC a registration statement on Form S-4 that will include a joint proxy statement of Uroplasty and Vision-Sciences that also constitutes a prosp

  4. Slide 4: The Merger

    The Merger - COGENTIX MEDICAL -- (NASDAQ: CGNT) - - Headquarters in Minnetonka, MN -- Merger expected to accelerate growth of combined companies -- Expands innovative product offerings in Urology - - Creates platform for growth in addressable $1.3 Billion flexible endoscopy market -The first step in

  5. Slide 5: Terms of the Merger

    Terms of the Merger All-stock transaction Uroplasty shareholders to own 62.5% and Vision-Sciences shareholders to own 37.5% upon completion of the merger (on diluted basis, excluding shares issuable upon conversion of notes and warrants held by Vision-Sciences’ Board Chairman, which were amended in

  6. Slide 6: Strategic Rationale for the Merger

    Strategic Rationale for the Merger Accelerate revenue growth of combined company to a level higher than either company could achieve on its ownLeverage the strength of our combined assetsInnovative technologies in EndoSheath® and Urgent PC® Uroplasty distribution platform – 44 U.S. reps and 8 Intl.

  7. Slide 7: Urology Market Dynamics

    Urology Market Dynamics Costs of practice are rising while reimbursement is relatively stablePatient population with urologic disorders is predominantly beyond middle age (> 55 years); growth in the senior population, along with the large volume of chronic conditions, is increasing patient demand La

  8. Slide 8: Uroplasty, Inc. (UPI)

    Uroplasty, Inc. (UPI) Committed to Offering Transformative Treatment Options to Voiding Dysfunction Patients Uroplasty: Changing Care to Change Lives Urgent PC® The Only Commercially Available Non-Drug, Non-Surgical Treatment for Overactive Bladder (OAB)Simple and effectiveClinical validationAttract

  9. Slide 9: AUA/SUFU Overactive Bladder Treatment Guideline

    AUA/SUFU Overactive Bladder Treatment Guideline

  10. Slide 10: 3rd Line Treatment Addressable U.S. Market; Urgent PC Adoption Drivers

    3rd Line Treatment Addressable U.S. Market Urgent PC® Adoption DriversRapidly Aging PopulationDemand for Minimally Invasive OptionsLower Risk of Adverse Events & Shorter Recovery TimesIncreasing Awareness of OABImproved Healthcare Economics

  11. Slide 11: Uroplasty Financial Highlights

    Uroplasty Financial Highlights Total Revenue Product Revenue Mix Geographic Revenue Mix Gross Margin Note: 3/31 Fiscal Year End

  12. Slide 12: Vision-Sciences at a Glance

    Company Summary Proprietary Technology Platform Vision-Sciences at a Glance Total Revenue Founded in 1987NASDAQ: VSCIHQ in Orangeburg, NYFY14 revenue: $17.1M98 team members at 9/30/14 Note: 3/31 Fiscal Year End

  13. Slide 13: The Growing Need Met by EndoSheath

    The Growing Need Met by EndoSheath® Cross-ContaminationA Significant Healthcare Issue“…at minimum, endoscope reprocessing problems… can lead to life-threatening infections.” Listed in the “Top 10” each of the last 5 years

  14. Slide 14: The EndoSheath Solution

    The EndoSheath® Solution Innovative technology ensures an “always ready, always sterile” endoscope

  15. Slide 15: Vision-Sciences Comparative Reprocessing

    Vision-Sciences Comparative Reprocessing

  16. Slide 16: This Combination Will...

    This Combination Will… Leverage the current capacity in Uroplasty’s 44 person U.S. sales team and 8 person International sales team; capitalize on existing relationships in urologyCreate a platform for growth in other specialties that currently perform endoscopic procedures in physician offices and

  17. Slide 17: Cogentix Medical: Financial Highlights

    Cogentix Medical: Financial Highlights Total Revenue Product Revenue Mix Forecasting revenue of approximately $50 million for fiscal year beginning April 1, 2015

  18. Slide 18: Cogentix Medical: Financial Profile

    Cogentix Medical: Financial Profile $41.7 million in fiscal year 2014$24.6 million for Uroplasty$17.1 million for Vision-SciencesAccelerating future revenue growthTTM revenue growth of 10.9%11% to 14% revenue growth anticipated for fiscal year beginning April 1, 201515% sustainable revenue growth an

  19. Slide 19: Depth & Breadth of Leadership Team; Growth Strategy

    Depth & Breadth of Leadership TeamDistribution Platform44 U.S. Sales Reps – Uroplasty12 U.S. Sales Reps - Vision Sciences8 International Sales RepsDistributor RelationshipsFunctional ExpertiseSalesMarketingRegulatoryQuality Reimbursement Cogentix Medical: Growth Strategy Licensing & acquisition oppo

  20. Slide 20: Cogentix Medical: Growth Strategies

    Cogentix Medical: Growth Strategies GoalsAcquire innovative assets at attractive valuations Accelerate revenue growth to 15% for products in portfolio Reward shareholders through improved valuationMetricsAnticipated near-term revenue of ~ $50 millionAspire to $100 million of revenue within three yea

  21. Slide 21: Summary Benefits to Shareholders

    Summary Benefits to ShareholdersCreates Medical Device company positioned for growthGreater scale and stronger financial profileAccelerated revenue growth anticipated by leveraging existing capacity of Uroplasty sales teamExpands product offerings in UrologyExtends platform for growth in addressable

  22. Slide 22: Cogentix Medical

    Cogentix 4\ Medical

Uroplasty — Merger or Acquisition (December 2014) on 6ix